Shilpa Medicare receives approval from USFDA for Irinotecan HCL Injection

01 Jan 2019 Evaluate

Shilpa Medicare has received US Food and Drug Administration (USFDA) approval for its ANDA Irinotecan HCL Injection USP, 40 mg/2mL and 100 mg/5mL (20mg/mL) Single Dose Vials. Irinotecan injection is used in the treatment of patients with metastatic carcinoma of the colon or rectum.

According to IQVIA MAT Q2 2018 data, the US market for Irinotecan HCL approximately $18 million

Shilpa Medicare produces and exports consistently high-quality Active Pharmaceutical Ingredients Fine Chemicals, intermediates, herbal products and speciality chemical products using sophisticated technology, meticulously following international specifications.

Shilpa Medicare Share Price

287.20 -0.20 (-0.07%)
02-Feb-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1628.90
Dr. Reddys Lab 1182.35
Cipla 1311.75
Zydus Lifesciences 879.25
Lupin 2128.60
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×